ARTERIAL THROMBOEMBOLIC EVENTS IN A POOLED ANALYSIS OF 5 RANDOMIZED, CONTROLLED TRIALS OF BEVACIZUMAB WITH CHEMOTHERAPY JR Skillings Genentech, Inc, South.

Slides:



Advertisements
Similar presentations
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
Robertson JFR et al. J Clin Oncol 2009;27(27):
ECCO ESMO 2011 GI Cancer Updates “ VELOUR” Study Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October.
PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
Estimating cancer survival and clinical outcome based on genetic tumor progression scores Jörg Rahnenführer 1,*, Niko Beerenwinkel 1,, Wolfgang A. Schulz.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Avastin ® : setting the standard in treatment for metastatic colorectal cancer (CRC) Fairooz Kabbinavar David Geffen School of Medicine at UCLA Los Angeles,
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
A Meta-Analysis of Overall Survival Data from Three Trials of Bevacizumab and First-Line Chemotherapy as Treatment for Patients with Metastatic Breast.
Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
Pritchard KI et al. Proc SABCS 2010;Abstract P
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
1 ABSTRACT #4036 (Sat. June 2, 2007: 2:00-6:00pm) Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival.
Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis.
ECCO ESMO 2011 GI Cancer Updates “VELOUR” Study
The SPRINT Research Group
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
Swain SM et al. Proc SABCS 2012;Abstract P
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
on behalf of the LEADER Trial Steering Committee and Investigators
Baselga J et al. SABCS 2009;Abstract 45.
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
Published online September 20, 2017 by JAMA Surgery
Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada
Volume 73, Issue 8, Pages (April 2008)
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Presentation transcript:

ARTERIAL THROMBOEMBOLIC EVENTS IN A POOLED ANALYSIS OF 5 RANDOMIZED, CONTROLLED TRIALS OF BEVACIZUMAB WITH CHEMOTHERAPY JR Skillings Genentech, Inc, South San Francisco, CA

BACKGROUND Bevacizumab (BV; Avastin TM ) is a recombinant, humanized, anti-vascular endothelial growth factor (VEGF) monoclonal antibody BV combined with first-line irinotecan, 5-fluorouracil (5-FU), and leucovorin (IFL) chemotherapy increases survival in patients with metastatic colorectal cancer (mCRC) Safety reports from several randomized, controlled trials suggested that adding BV to chemotherapy may increase the risk of arterial thromboembolic events (ATEs)

OBJECTIVE To evaluate the risk of ATEs in patients with metastatic cancer receiving BV with chemotherapy using data pooled from 5 randomized, controlled trials

METHODS: STUDY DESIGN CAP=capecitabine; C=carboplatin; P=paclitaxel MBC= metastatic breast cancer; NSCLC=non-small-cell lung cancer 1 Hurwitz H, et al. N Engl J Med. 2004;350: ; 2 Kabbinavar F, et al. J Clin Oncol In Press; 3 Kabbinavar F, et al. J Clin Oncol. 2003;21:60-65; 4 Miller K, et al. J Clin Oncol. 2005; 23: ; 5 Johnson D, et al. J Clin Oncol. 2004;22:

METHODS: IDENTIFICATION OF ATE CASES The pooled database was broadly queried for adverse event terms that might be associated with the clinical consequences of ATEs The following COSTART terms were used for the initial search: cerebrovascular accident, cerebral ischemia, subarachnoid hemorrhage, cerebral infarction, angina pectoris, myocardial infarction, myocardial ischemia, and arterial thrombosis. Thrombosis and verbatim terms including left ventricle were added Death due to causes other than progressive disease were clinically reviewed for text fields including cerebrovascular accident, myocardial infarction or ATE. A case of ischemic bowel was added The safety database was reviewed using broad search criteria and one additional case of right leg arterial occlusion was added Cases of subarachnoid hemorrhage were removed because these were interpreted as bleeding events Cases of cardiac arrest were removed when review of narratives suggested that the cases were related to progressive disease A combined list of cases was identified

METHODS: IDENTIFIED TREATMENT-EMERGENT ATEs Angina pectorisMyocardial infarction Arterial thrombosisMyocardial ischemia Cerebral infarctionEmbolism Cerebral ischemiaArterial occlusion Cerebrovascular accident Left ventricle thrombosis Ischemic bowel

METHODS: STATISTICAL ANALYSIS Incidence of ATEs was tabulated for each treatment group Kaplan-Meier plots of time-to-ATE were generated for each treatment group and median values estimated. A Cox proportional hazards regression was used to calculate hazard ratios, and P-values were calculated by the log-rank test ATE rates per 100 person-years with 95% confidence intervals were computed by standard methods. The number of person- years of observation was defined as the sum of the time-to-ATE for all patients (for patients without an ATE, the observation time was defined as the last date of treatment plus 30 days) Poisson regression was used to formally compare rates per 100 person-years between BV-treated patients and controls

METHODS: BASELINE VARIABLES USED FOR POTENTIAL RISK FACTOR ANALYSIS DBP=diastolic blood pressure; HTN=hypertension; SBP=systolic blood pressure

METHODS: OTHER BASELINE VARIABLES USED FOR POTENTIAL RISK FACTOR ANALYSIS TIA=transient ischemic attack

METHODS: POTENTIAL RISK FACTOR ANALYSIS For each risk factor, numbers of patients with and without the factor were tabulated Fisher’s exact test was used to compare the frequency of ATEs between BV-treated and control patients for each risk factor Cox’s proportional hazards regression was used to compute hazard ratios and P-values for the effect of each factor on the hazard of ATEs Backward elimination in a multivariate Cox model was used to assess the significance of each baseline risk factor that was significant in univariate analysis Pooled population patients were assigned to subgroups based on significant baseline risk factors, and ATE rates per 100 person-years were calculated as described above within each subgroup by treatment Irinotecan-treated patients from the pivotal trial in mCRC (AVF2107g) 1 were assigned to subgroups based on these risk factors. Median PFS and overall survival were estimated for each subgroup using Kaplan-Meier methods, and hazard ratios were calculated from a Cox proportional hazards model 1 Hurwitz H, et al. N Engl J Med. 2004;350:

RESULTS: INCIDENCE OF ATEs FOR EACH TREATMENT GROUP 1 Hurwitz H, et al. N Engl J Med. 2004;350: ; 2 Kabbinavar F, et al. J Clin Oncol In Press; 3 Kabbinavar F, et al. J Clin Oncol. 2003;21:60-65; 4 Miller K, et al. J Clin Oncol. 2005; 23: ; 5 Johnson D, et al. J Clin Oncol. 2004;22: MBC= metastatic breast cancer; NSCLC=non-small-cell lung cancer

RESULTS: ATE ANALYSIS CI=confidence interval *P=0.076; **P=0.03

Uncorrected for uneven time on treatment and shorter follow up for control patients Months control chemo/AVF Patients at risk by time point RESULTS: KAPLAN-MEIER TIME-TO-ATE

RESULTS: ATE POTENTIAL RISK FACTORS IN UNIVARIANT ANALYSIS DBP=diastolic blood pressure; HTN=hypertension; SBP=systolic blood pressure *On study indicates occurrence during treatment (and prior to an ATE if one occurred) † Collected in selected trials Hurwitz H, et al. N Engl J Med. 2004;350: ; 2 Kabbinavar F, et al. J Clin Oncol In Press; 3 Miller K, et al. J Clin Oncol. 2005; 23:

RESULTS: RELATIONSHIP BETWEEN ATEs AND PROTEINURIA Patients with proteinuria (>500mg/24 hours) are at risk of ATEs regardless of treatment. The explanation for this finding is unclear Proteinuria (>500mg/24 hours) n=subset; N=total number

RESULTS: BASELINE ATE RISK FACTORS SIGNIFICANT IN MULTIVARIATE ANALYSIS In a multivariate analysis with both baseline and on-study factors, no on-study factors were significant except presence of proteinuria >500mg/24 hours In a separate multivariate analysis with only on-study factors, presence of proteinuria alone was significant

RESULTS: RISK/BENEFIT OF BV in mCRC To understand the risk/benefit of BV in mCRC, data from the pivotal trial AVF were reanalyzed* for survival based on subgroups created using risk factors for ATEs 1 Hurwitz H, et al. N Engl J Med. 2004;350: *The dataset used to support the preplanned final analysis for AVF2107g was used for this analysis

RESULTS: ATE INCIDENCE BY RISK GROUP n=subgroup; N=total number *These groups are not mutually exclusive

RESULTS: SURVIVAL HAZARD RATIOS IN mCRC BY RISK GROUP 1 Hurwitz H, et al. N Engl J Med. 2004;350: CI=confidence interval; PFS=progression-free survival *These groups are not mutually exclusive

CONCLUSIONS Bevacizumab is associated with an approximately 2-fold increased risk of ATEs in patients with metastatic cancer receiving chemotherapy Age ≥65 years and a history of ATEs are independent baseline risk factors for these events

CONCLUSIONS (cont’d) Despite this risk, analysis of data from the pivotal trial 1 indicate that bevacizumab confers a consistent survival benefit in mCRC patients overall, in all prespecified subgroups, and in these ATE risk subgroups Oncologists must use their own clinical judgment in assessing the overall risk/benefit of adding bevacizumab to chemotherapy in patients at risk of ATEs 1 Hurwitz H, et al. N Engl J Med. 2004;350: